Aescin: Herbal Active Ingredient from Horse Chestnut Seeds for Venous Insufficiency

Aescin is a complex mixture of triterpenoid saponins from the seeds of the horse chestnut (Aesculus hippocastanum). The main component is beta aescin, a mixture of aescin Ia and Ib. In Germany, aescin has been approved for decades as a phytotherapeutic agent for the treatment of chronic venous insufficiency and edematous swelling following injuries. Well known brand names include Venostasin, Venogel, Reparil, and Aesculaforce.

The horse chestnut has a long tradition in folk medicine. Only the structural elucidation of aescin in the 1950s and controlled clinical studies starting in the 1980s introduced the plant into scientific phytotherapy. In a Cochrane review (Pittler and Ernst, updated multiple times), aescin is rated as effective against leg edema, heaviness, itching, and pain in chronic venous insufficiency, comparable to compression stockings class II.

Mechanism of Action

Venous insufficiency is characterized by elevated venous pressure, damage to valves and endothelium, and increasing permeability of capillary walls. Fluid, proteins, and red blood cells escape into the tissue and cause edema, hyperpigmentation, and eventually trophic skin changes.

Aescin acts at multiple levels of this pathophysiology. It inhibits the enzyme hyaluronidase, which breaks down the glycosaminoglycans of the vessel wall, thereby stabilizing the vessel structure. It reduces the permeability of capillary walls without reducing blood flow. In addition, it inhibits proinflammatory mediators and reduces the activation of inflammatory cells at the endothelium. Furthermore, aescin increases venous tone by sensitizing the venous wall to calcium ions, which alleviates orthostatic stasis.

The oral bioavailability of aescin is low at approximately 1.5 percent, yet the plasma levels achieved are sufficient for the clinically observed effects. When applied topically (gel, ointment), aescin is applied locally and acts predominantly on the skin surface.

Indications

• Chronic venous insufficiency stage I to II according to Widmer: heaviness, pain, itching, cramps, evening swelling of the legs
• Blunt injuries: topical application for contusions, sprains, hematomas
• Postoperative and post-traumatic edema: following procedures, sports injuries
• Hemorrhoids: as supportive therapy for venous congestion
• Lymphedema: off label as adjunctive medication, manual lymphatic drainage remains the primary treatment

Dosage and Administration

Oral, standard formulation: 50 mg aescin (corresponding to approximately 250 mg dry extract) twice daily. Extended-release formulation: 50 to 75 mg aescin once daily. Onset of action after two to four weeks, significant improvement after eight to twelve weeks of therapy.

Topical: apply gel or ointment two to four times daily to the affected area in a thin layer and massage in. Begin as soon as possible for hematomas and contusions.

Renal and hepatic insufficiency: in case of impaired function, oral aescin should be used only under medical supervision. In severe renal insufficiency there is an increased risk of nephrotoxicity.

Side Effects

Common: gastrointestinal complaints such as nausea, heartburn, abdominal pain, especially at the beginning of therapy. Allergic skin reactions with topical application (itching, redness).

Occasional to rare: dizziness, headache, skin rash, allergic reaction including systemic reactions. At very high oral doses or with intravenous doses, cases of nephrotoxicity and hepatotoxicity were described in older reports, leading to discontinuation of intravenous use in Germany. The oral phytopharmaceuticals available today are considered well tolerated.

Important: patients with known allergy to horse chestnut components should avoid aescin. When swelling presents with tension pain, warmth, and redness, deep vein thrombosis may be present, which requires medical evaluation and cannot be replaced by phytotherapy.

Drug Interactions

• Anticoagulants (phenprocoumon, warfarin, DOACs): aescin is highly bound to albumin in the bloodstream and can displace other strongly albumin-bound active substances; INR and bleeding risk may theoretically increase; relevant cases are rarely described, INR monitoring is recommended
• Aminoglycoside antibiotics: theoretical additive nephrotoxicity, clinically poorly documented
• NSAIDs: with long-term combination possible additive gastrointestinal irritation
• Other phytotherapeutics for venous insufficiency (diosmin, hesperidin, buckwheat): additive effect possible, rarely prescribed together in clinical practice

Special Precautions

Pregnancy and lactation: data on oral use in pregnancy are limited, phytopharmaceuticals are generally used cautiously in early pregnancy. Topical application is considered safe. Data are lacking for lactation, use should be decided on an individual basis.

Compression therapy as gold standard: aescin supplements compression therapy and does not replace it. At stage II and beyond chronic venous insufficiency, medical compression stockings class II and III are basic therapy, supplemented by exercise, leg elevation, and weight reduction if overweight.

Differential diagnosis: unilateral acute leg swelling may indicate deep vein thrombosis and requires immediate diagnostic evaluation with D-dimer and ultrasound. Aescin is not a substitute for medical evaluation here.

Duration of therapy: long-term use over months is possible, regular medical monitoring of liver and kidney values during long-term therapy is advisable.

You might also be interested in

• Diosmin, another bioflavonoid for venous insufficiency
• Rutosid, bioflavonoid with similar indication
• Heparin, anticoagulant therapy for thrombosis
• Troxerutin, semisynthetic flavonoid
• Oxerutin, another venotonic active substance

Frequently Asked Questions

Sources

• Cochrane Review Pittler MH, Ernst E, Horse chestnut seed extract for chronic venous insufficiency
• Gelbe Liste, Aescin active ingredient profile
• AWMF guideline chronic venous insufficiency and phlebology
• BfArM, Federal Institute for Drugs and Medical Devices